Growth in number of patients suffering from conditions such as hypertension and heart failure is expected to drive aldosterone receptor antagonists market

WILMINGTON, DELAWARE, UNITED STATES, September 20, 2023/EINPresswire.com/ -- Transparency Market Research - The Aldosterone Receptor Antagonists Market stood at USD 2.4 bn in 2022 and it is expected to reach USD 4.5 bn by 2031 with CAGR of 7.1%. Rapid increase in usage of mineralocorticoid-receptor antagonists (mra) to treat patients with heart failure and various forms of hypertension, such as resistant hypertension, is expected to augment the global aldosterone receptor antagonists market. Therapies based on aldosterone receptor antagonists are likely to become popular to treat cardiovascular diseases.

𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐕𝐢𝐛𝐫𝐚𝐭𝐢𝐧𝐠 𝐌𝐞𝐬𝐡 𝐍𝐞𝐛𝐮𝐥𝐢𝐳𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85448

Adoption of aldosterone receptor antagonist agents to improve renal function has increased significantly among patients suffering from chronic kidney diseases. These drugs work primarily by blocking epithelial and non-epithelial actions of aldosterone. These are effective in improving cardiovascular prognosis in patients after myocardial infarction. Rise in utilization of medications in tablet form is expected to augment the aldosterone receptor antagonists market outlook. Recent advances in third-generation MR antagonists are likely to bolster the market in the near future.

The healthcare industry is keen on reducing the cost of medications based on aldosterone receptor antagonists in order to make these affordable to people especially in low- and middle-income countries. Significant adoption of steroidal MRAs to treat and manage patients with heart failure is fueling the aldosterone receptor antagonists market industry. Increase in adoption is ascribed to availability of generic medicines based on steroidal MRAs.
Key Drivers

Rise in elderly population is driving the demand for drugs based on aldosterone receptor antagonists to treat heart failure and resistant hypertension. A few mineralocorticoid-blocking agents have been extensively utilized as a therapy to reduce blood pressure.

High prevalence of hypertension and heart failure in populations globally is expected to bolster the aldosterone receptor antagonists market development
Continuous advancements in drugs have led to availability of medications that effectively reduce the biological effects of aldosterone in the patient population and improve cardiovascular outcomes.

Companies Profiled:

• RPG Life Sciences Limited (RPG Group)
• Bayer AG
• CMP Pharma
• AdvaCare Pharma
• Gedeon Richter Plc.
• Sanofi
• INTRA INVENTURE
• A-S Medication Solutions, LLC
• Viatris Inc. (Mylan N.V.)

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞 - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85448

Aldosterone Receptor Antagonists Market Segmentation

Drug Type
• Steroidal Mineralocorticoid Receptor Antagonists
• Non-steroidal Mineralocorticoid Receptor Antagonists
Dosage Form
• Tablets
• Suspensions
• Capsules
• Creams & Gels

Indication
• Hypertension
• Heart Failure
• Edema
• Primary Aldosteronism
• Others

Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐥𝐞𝐭𝐬 𝐲𝐨𝐮 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐭𝐡𝐞 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐀𝐥𝐝𝐨𝐬𝐭𝐞𝐫𝐨𝐧𝐞 𝐑𝐞𝐜𝐞𝐩𝐭𝐨𝐫 𝐀𝐧𝐭𝐚𝐠𝐨𝐧𝐢𝐬𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐦𝐞𝐚𝐧𝐬 𝐨𝐟 𝐚 𝐫𝐞𝐠𝐢𝐨𝐧:

• North America (the United States, Canada, and Mexico)
• Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
• Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
• South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲? 𝐀𝐬𝐤 𝐓𝐨 𝐀𝐧𝐚𝐥𝐲𝐬𝐭: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85448

𝗦𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗸𝗲𝘆 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝘀𝗰𝗿𝘂𝘁𝗶𝗻𝗶𝘇𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗮𝗿𝗲:

• What are some of the recent brand building activities of key players undertaken to create customer value in the Aldosterone Receptor Antagonists market?
• Which companies are expanding litany of products with the aim to diversify product portfolio?
• Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Aldosterone Receptor Antagonists market?
• Which companies have expanded their horizons by engaging in long-term societal considerations?
• Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?
• What are the marketing programs for some of the recent product launches?

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 –

Hyperthermia Cancer Treatment Market : Hyperthermia is a form of therapy where heat is used to enhance effectiveness of radiation and chemotherapy, and to destroy tumors. Hyperthermia is most often used to treat tumors that are close to the surface of the body.

Bioresorbable Vascular Scaffold Market : Bioresorbable vascular scaffold (BVS) is a medical device that can be used to treat coronary artery disease. It is a type of stent made of a biodegradable polymer material that dissolves over time, leaving behind only the natural vessel.

Nikhil Sawlani
Transparency Market Research Inc.
+18665523453 ext.
email us here
Visit us on social media:
Twitter
LinkedIn
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.